[HTML][HTML] Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials
J An, JH Sohn - Clinical and Molecular Hepatology, 2023 - ncbi.nlm.nih.gov
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
[PDF][PDF] Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on glob-al results of randomized controlled trials
J An, JH Sohn - 2023 - core.ac.uk
Nonalcoholic fatty liver disease (NAFLD) affects approximately one-quarter of the adult
population worldwide, making it the most common liver disease. 1 Nonalcoholic …
population worldwide, making it the most common liver disease. 1 Nonalcoholic …
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials
JH An, JH Sohn - Clinical and Molecular Hepatology, 2023 - oldkmbase.medric.or.kr
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials
J An, JH Sohn - Clinical and Molecular Hepatology, 2023 - dbpia.co.kr
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials
J An, JH Sohn - Clinical and molecular hepatology, 2023 - pubmed.ncbi.nlm.nih.gov
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials
J An, JH Sohn - Clinical and Molecular Hepatology - KoreaMed
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials
J An, JH Sohn - CLINICAL AND MOLECULAR …, 2023 - scholarworks.bwise.kr
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
[HTML][HTML] Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials
J An, JH Sohn - Clinical and Molecular Hepatology, 2022 - e-cmh.org
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
[HTML][HTML] Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials
J An, JH Sohn - Clinical and Molecular Hepatology, 2022 - e-cmh.org
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials.
J An, JH Sohn - Clinical and Molecular Hepatology, 2022 - europepmc.org
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …
globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a …